undamentalytics Newsletter
Sign in

Dyne Therapeutics, Inc. (DYN) stock

Add to watchlist

Add holding +

NASDAQ: DYN Nasdaq Biotechnology Next results ~November 5, 2026

Dyne Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 6 selling8 purchases and 122 sales by directors and officers, last 12 monthsInsider trades
  • Funds130 adding, 104 cuttingOf 53 active managers that changed their stake, 25 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 44% in the quarter to 2026-06-30.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Dyne Therapeutics, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Volatile shares. Over the past year the shares showed annualised volatility of 66% and a beta of 1.8 against the S&P 500.
  • Heavily shorted. 17.4% of the shares available to trade are sold short (7.9 days of average volume to cover).

Latest results

Earnings per share
-$1.08 against an average estimate of -$0.75: missed by 44.3%
Share reaction
-0.7% in the first session after the results on July 29, 2026, against +0.1% for the S&P 500
Next report
November 5, 2026; average EPS estimate -$0.88

Dyne Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+3.7%
  • 1 week+10.1%
  • 1 month+13.8%
  • This year-11.6%
  • 1 year-23.4%
  • 5 years+17.5%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
July 29, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Insider trade
  3. Insider trade
  4. Results
  5. Insider trade
  6. Agreement
  7. Announcement
  8. Insider trade

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Dyne Therapeutics, Inc. valuation models and calculator

No model value for Dyne Therapeutics, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, after the close. Analysts expect revenue of $0 and EPS of −$0.88 (range −$1.09 to −$0.65) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$3.53 −2% — 0%
Next −$3.31 +6% $53m 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +0.4% on 90 days ago. In the last 30 days, 1 analyst raised Dyne Therapeutics, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Dyne Therapeutics, Inc., last 90 days
−$4.00 −$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$3.51 Current fiscal year, 60 days ago: −$3.57 Current fiscal year, 30 days ago: −$3.55 Current fiscal year, 7 days ago: −$3.55 Current fiscal year, Now: −$3.53 −$3.53 Next fiscal year, 90 days ago: −$3.18 Next fiscal year, 60 days ago: −$3.34 Next fiscal year, 30 days ago: −$3.34 Next fiscal year, 7 days ago: −$3.34 Next fiscal year, Now: −$3.31 −$3.31

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$3.51−$3.18
60 days ago −$3.57−$3.34
30 days ago −$3.55−$3.34
7 days ago −$3.55−$3.34
Now −$3.53−$3.31

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.75 −$1.08 −44.3%
Mar 2026 −$0.78 −$0.73 +6.7%
Dec 2025 −$0.76 −$0.73 +4.4%
Sept 2025 −$0.85 −$0.76 +10.1%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

17 analysts, Oct 2026
Buy1588%
Hold16%
Sell16%

Monthly trend

  1. Oct 202631217
  2. Sep 202631317
  3. Aug 202631317
  4. Jul 202631317

Counts of recommendations published by analysts covering Dyne Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
17.4%
of tradable shares
Days to cover
7.94
at average volume
Short interest, 1 month
+9%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
0.2%
of shares
Employees
289
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
DYN−43%−3%+15%+77%−17%−12%
Industry peers (median)−35%−57%−18%−29%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
DYN17%50%42%67%42%64%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
DYN−59%−65%−56%−50%−73%−47%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since September 17, 2020: 86% from August 21, 2024 to April 8, 2025. Getting back needed a 591% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$14.25 – $26.78
From 52-week high
−35.4%
vs 50-day average
−5.8%
vs 200-day average
−10.4%
Volatility (1 year)
66%
Beta vs S&P 500
1.84

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±9.8%
After a week
7 up, 5 down
typical move ±10.8%
After a month
6 up, 6 down
typical move ±19.2%
Results releasedNext dayS&P 500 next day5 days21 days
July 29, 2026 −0.7% +0.1% +1.0% +0.7%
May 11, 2026 +4.3% +0.1% −6.1% +0.3%
March 2, 2026 −6.5% −0.8% +13.3% +16.1%
January 12, 2026 −4.1% 0.0% −6.7% −6.1%
November 5, 2025 −15.4% −0.7% −13.5% −5.8%
July 28, 2025 −7.5% −0.3% +3.0% +34.5%
May 8, 2025 +21.4% +0.6% +24.9% +53.2%
February 27, 2025 −1.3% −0.1% −11.2% −17.0%
January 10, 2025 −33.7% −1.4% −38.7% −41.3%
November 12, 2024 +21.3% −0.3% +5.5% −9.0%
August 12, 2024 +0.1% +1.7% +5.8% −25.2%
May 2, 2024 +1.0% +2.2% +0.5% +21.6%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$4.2B
Institutions reporting
245
Shares held vs prior quarter
▲ 1.2%
Positions opened / closed
42 / 28

Top buyers and sellers, Q2 2026: 130 institutions bought and 104 sold ; the biggest buyer was FMR LLC (+2.3M shares) and the biggest seller Atlas Venture Life Science Advisors, LLC (−2.3M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
T. Rowe Price Investment Management, Inc. $687M 30.9M 16.2% ▲ 0.4%
Blackrock, Inc. $276M 12.4M 6.5% ▲ 6.0%
Jupiter Topco LLC $267M 12.0M 6.3% —
FMR LLC $249M 11.2M 5.9% ▲ 25.8%
State Street Corp $166M 7.5M 3.9% ▲ 12.1%
Orbis Allan Gray Ltd $156M 7.0M 3.7% ▲ 3.6%
Atlas Venture Life Science Advisors, LLC $151M 6.8M 3.6% ▼ 25.5%
Vanguard Capital Management LLC $140M 6.3M 3.3% ▼ 1.5%
Tcg Crossover Management, LLC $103M 4.6M 2.4% 0.0%
Vanguard Portfolio Management LLC $89.9M 4.0M 2.1% ▼ 2.7%
Price T Rowe Associates Inc $87.4M 3.9M 2.1% ▲ 69.1%
Fcpm Iii Services B.V. $85.5M 3.8M 2.0% ▼ 17.1%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Dyne Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $314,840 8 trades by 1 insider, last 12 months Insider sales History → $169M 122 trades by 6 insiders · 100% under pre-set plans
Net ▼ $168M net selling
Insider Date Trade Shares Price Value
Posner Brian S Director October 2, 2026 Buy 2,500 $16.00 $40,000
Cox John CEO & President September 8, 2026 Sell pre-set plan 5,658 $18.88 $106,823
Kerr Douglas Chief Medical Officer September 8, 2026 Sell pre-set plan 1,290 $18.88 $24,355
Friedl-Naderer Johanna Chief Commercial Officer September 8, 2026 Sell pre-set plan 185 $18.88 $3,493
Kerr Douglas Chief Medical Officer September 4, 2026 Sell pre-set plan 3,745 $24.35 $91,191
Friedl-Naderer Johanna Chief Commercial Officer September 4, 2026 Sell pre-set plan 900 $24.35 $21,915
Rhodes Jason P Director August 14, 2026 Sell pre-set plan 322,465 $25.00 $8.1M
Rhodes Jason P Director August 14, 2026 Sell pre-set plan 478,377 $25.00 $12M
Rhodes Jason P Director August 14, 2026 Sell pre-set plan 1,359,674 $25.00 $34M
Lucera Erick Chief Financial Officer August 13, 2026 Sell pre-set plan 1,797 $26.28 $47,225
Cox John CEO & President August 13, 2026 Sell pre-set plan 4,986 $26.28 $131,032
Kerr Douglas Chief Medical Officer August 13, 2026 Sell pre-set plan 1,556 $26.28 $40,892

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around October 7, 2026 estimated from the company's past filing pattern, not announced

  • July 29, 2026
  • May 11, 2026
  • March 2, 2026
  • January 12, 2026
  • November 5, 2025
  • July 28, 2025

Recent SEC filings

Data status

When each part of this page on Dyne Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Dyne Therapeutics, Inc. in brief

What does Dyne Therapeutics, Inc. do?
Dyne Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Dyne Therapeutics, Inc.'s stock ticker?
Dyne Therapeutics, Inc. trades under the ticker DYN on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Dyne Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are T. Rowe Price Investment Management, Inc., Blackrock, Inc. and Jupiter Topco LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Dyne Therapeutics, Inc. stock?
Over the last 12 months, Dyne Therapeutics, Inc.'s directors and officers reported 8 open-market purchases and 122 sales on Form 4. The insider trading page charts every trade.
When is Dyne Therapeutics, Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Dyne Therapeutics, Inc. announces its own schedule.